Life Sciences Research for Lifelong Health
lab photo hero

Klaus Okkenhaug

Klaus obtained his B.Sc. in Biochemistry from the University of Victoria, British Columbia, Canada, followed by a Ph.D. in Immunology from the University of Toronto, where he studied CD28 signalling in Rob Rottapel’s lab. In 1999, he moved to London, UK, where he joined Bart Vanhaesebroeck’s group at the Ludwig Institute for Cancer Research as a Postdoctoral Fellow, working on the role of p110δ in immune responses. Klaus joined the Laboratory of Lymphocyte Signalling Lab and Development at the Babraham Institute as a Group Leader in 2003.

01223 333726

Email Klaus

Latest Publications

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.

Chellappa S, Kushekhar K, Munthe LA

Journal of immunology (Baltimore, Md. : 1950)
1550-6606: (2019)

PMID: 30692213

PI3K induces B-cell development and regulates B cell identity.

Abdelrasoul H, Werner M, Setz CS

Scientific reports
8 2045-2322:1327 (2018)

PMID: 29358580

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H

Immunity
47 1097-4180:875-889.e10 (2017)

PMID: 29166588

Multi-tissue DNA methylation age predictor in mouse.

Stubbs TM, Bonder MJ, Stark AK

Genome biology
18 1474-760X:68 (2017)

PMID: 28399939

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Okkenhaug K, Graupera M, Vanhaesebroeck B

Cancer discovery
2159-8290: (2016)

PMID: 27655435

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Eil R, Vodnala SK, Clever D

Nature
537 1476-4687:539-543 (2016)

PMID: 27626381

PI3Kδ and primary immunodeficiencies.

Lucas CL, Chandra A, Nejentsev S

Nature reviews. Immunology
1474-1741: (2016)

PMID: 27616589